Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows
Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives of men with metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting, data from more than 6,000  Medicare patients shows. The findings were presented in a poster titled “Overall survival (OS) among Medicare beneficiaries receiving sipuleucel-T (sip-T) versus oral treatment for metastatic castration-resistant prostate cancer (mCRPC),” at the recent American Society of Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium in San Francisco, California. Provenge, marketed by Dendreon Pharmaceuticals, is an immunotherapy that uses a patient’s own immune cells to fight prostate cancer. In it, a fraction of white blood cells that have been exposed to a prostate cancer protein are primed to activate the remaining immune cells to fight cancer. Provenge is the only immunotherapy approved in the U.S. for prostate cancer that is made from a patient’s own immune cells. It was approved in 2010 based on data from the IMPACT Phase 3 trial (NCT00065442), which showed that Provenge significantly extended mCRPC patients' lives compared to a placebo. Since then, second-generation androgen receptor inhibitors, like Zytiga and Xtandi, not yet approved at the time of IMPACT, have become the standard care treatment for men with mCRPC. This led researchers at Dendreon to assess the benefits of Provenge when used in combination with these agents. The researchers examined medical and pharmacy claims from 6,853 Medicare mCRPC patients who had not received any prior treatment, which means they had no treatment claims in the prior year. Results indicated that the use o
Subscribe or to access all post and page content.